

'Blood use in intensively treated AML patients in the Netherlands'

- Aims:**
- Describe differences in blood use in trials between centers and treatment arms (RBC, PLT, plasma)
 - Describe differences in transfusion triggers between centers
 - Generate evidence for best/ practical transfusion guidelines for studies and daily practice (baseline measurement)
- Patients:**
- AML patients in HOVON 29, 42, 92 or 102 in NL, at least 2 courses of chemotherapy + CR1 after one or two courses
- Methods:**
- Retrospective observational research
 - HOVON database, clinical chemistry/transfusion labs
- Status:**
- @ Medical Ethical Board LUMC
 - Expected start of data collection Q3 2017

Your participation will be greatly appreciated!